Although DUSP4 expression has been reported previously in skin melanomas, and as a potential biomarker for patient response to MEK inhibition with its upregulation correlating with a positive response [61,62], it has not been described previously in UM. This evidence concerns the gene MAP2K7 and cutaneous melanoma.